CHICAGO, IL – November 1, 2022 – Renalogic, the leading company helping employers and self-funded health plans fight the human and financial costs of chronic kidney disease (CKD) and end-stage renal disease (ESRD), announces certification from the Validation Institute for savings.
Since 2014, the Validation Institute has been advocating for better health value and offering approaches for strong health outcomes at lower costs. They connect, train, and certify healthcare purchasers in addition to validating that providers are delivering high-quality care with superior results.
Organizations pursuing a certification from the Validation Institute must go through a rigorous review process by a team of epidemiologists and statisticians. The assessment of each program focuses on evidence, reliability, credibility, and approach.
After a thorough evaluation, Renalogic’s ImpactProtect Program was recognized for savings. The Validation Institute found that Renalogic’s contract pricing is up to 85% lower than the plan’s Allowed Amount. The analysis included claims from 90 patients that occurred in 2022. The results showed that Renalogic’s ImpactProtect program cut the plan’s 12-month costs by $17.5 million. The claims consisted of services including kidney dialysis, lab tests, drugs, vaccines, and supplies during dialysis procedures.
Renalogic is dedicated to managing the risks and costs associated with dialysis and chronic kidney disease (CKD). Their programs, like ImpactProtect, work to provide an end-to-end solution for identifying the risk of renal disease, providing specific management programs for CKD, and offering industry-leading cost-containment services.
For more information about Renalogic, visit www.renalogic.com.
For more information about Validation Institute, visit https://validationinstitute.com/.
